 The FDA policies exist. What we need to do is be able to take advantage of those specifically in transplant. And I think that the stall is that the division that reviews transplant drugs is very interested in continuing to use the traditional endpoint that's based on rejection. So we need to augment that endpoint and also use a new endpoint. And the other stall, I think, is that